Health-related quality of life in patients with neurofibromatosis type 1: A survey of 129 Italian patients

Dermatology

Volumn 218, Issue 3, 2009, Pages 215-220

  Kodra, Yllka ^a   Giustini, Sandra ^a   Divona, Luigina ^a   Porciello, Roberto ^a   Calvieri, Stefano ^a   Wolkenstein, Pierre ^b   Taruscio, Domenica ^a,c  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b HENRI MONDOR HOSPITAL   (France)

^c ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

Neurofibromatosis type 1; Quality of life; SF 36 questionnaire; Skindex 29

Indexed keywords

ADULT; AGED; ARTICLE; CLINICAL ASSESSMENT; CONTROLLED STUDY; CROSS-SECTIONAL STUDY; DISEASE ASSOCIATION; DISEASE SEVERITY; EMOTIONAL STABILITY; FEMALE; HUMAN; ITALY; MAJOR CLINICAL STUDY; MALE; NEUROFIBROMATOSIS; NEUROFIBROMATOSIS TYPE 1; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE;

ADOLESCENT; ADULT; AGED; FEMALE; HEALTH STATUS; HUMANS; INTERPERSONAL RELATIONS; ITALY; MALE; MIDDLE AGED; NEUROFIBROMATOSIS 1; QUALITY OF LIFE; QUESTIONNAIRES; YOUNG ADULT;

EID: 62049084689     PISSN: 10188665     EISSN: None     Source Type: Journal    
DOI: 10.1159/000187594     Document Type: Article

References (14)

1. Poyhonen M: A clinical assessment of neurofibromatosis type 1 (NF1) and segmental NF in northern Finland. J Med Genet 2000;37:E43.
2. North K: Neurofibromatosis type 1: review of the first 200 patients in an Australian clinic. J Child Neurol 1993;8:395-402.
3. Friedman JM: Epidemiology of neurofibromatosis type 1. Am J Med Genet 1999;89:1-6.
4. Pinson S, Wolkenstein P: La neurofibromatose 1 (NF1) ou maladie de Von Recklinghausen. Rev Med Interne 2005;26:196-215.
5. Karwacki MW, Wozniak W: Neurofibromatosis - an inborn genetic disorder with susceptibility to neoplasia (in Polish). Med Wieku Rozwoj 2006;10:923-948.
6. Apolone G, Mosconi P, Ware John JR: Questionario sullo stato di salute SF-36: manuale d'uso e guida all'interpretazione dei risultati. Milano, Guerini e Associati, 1998.
7. Ablon J: Gender response to neurofibromatosis 1. Soc Sci Med 1996;42:99-109.
8. Wolkenstein P, Zeller J, Revuz J, Ecosse E, Leplege A: Quality-of-life impairment in neurofibromatosis type 1: a cross-sectional study of 128 cases. Arch Dermatol 2001;137:1421-1425.
9. Page PZ, Page GP, Ecosse E, Korf BR, Leplege A, Wolkenstein P: Impact of neurofibromatosis 1 on quality of life: a cross-sectional study of 176 American cases. Am J Med Genet A 2006;140:1893-1898.
10. Abeni D, Picardi A, Puddu P, Pasquini P, Chren MM: Lo Skindex-29, un nuovo strumento per la valutazione della qualitàdella vita in dermatologia. G Ital Dermatol Venereol 2001;136:73-76.
11. Sampogna F, Tabolli S, Mastroeni S, Di Pietro C, Fortes C, Abeni D; Italian Multipurpose Psoriasis Research on Vital Experiences (IMPROVE) study group: Quality of life impairment and psychological distress in elderly patients with psoriasis. Dermatology 2007;215:341-347.
12. Sampogna F, Gisondi P, Melchi CF, Amerio P, Girolomoni G, Abeni D: Prevalence of symptoms experienced by patients with different clinical types of psoriasis. Br J Dermatol 2004;151:594-599.
13. Nijsten T, Sampogna F, Stern RS, Abeni D: The Reduced Impact of Psoriasis Questionnaire has good psychometric properties in Italian patients. Dermatology 2007;215:348-351.
14. Le Cleach L, Chassany O, Levy A, Wolkenstein P, Chosidow O: Poor reporting of quality of life outcomes in dermatology randomized controlled clinical trials. Dermatology 2008;216:46-55.